Cited by 293Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

Open access

Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., Morris, A. D.·2006·Diabetologia

DOI 10.1007/s00125-006-0176-9

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis The aim of this study was to evaluate the risk of adverse cardiovascular outcomes in patients with type 2 diabetes newly treated with sulfonylureas and metformin.Subjects and methods The Diabetes Audit and Research in Tayside Scotland (DARTS) diabetes information system and the Medicines Monitoring Unit (MEMO) dispensed prescribing database for the population of Tayside, Scotland (400,000 people) were employed. Patients newly prescribed with oral hypoglycaemic agents between 1994 and 2001 were classified into five study cohorts according to the treatment received: metformin only, sulfonylureas only, sulfonylureas added to metformin, metformin added to sulfonylureas, and both drugs simultaneously. In Cox regression analyses, we estimated relative risks for all-cause mortality, cardiovascular mortality and cardiovascular hospital admission for patients in the five study cohorts, with metformin monotherapy as the reference group.Results Of the 5,730 study patients, 1,000 died during a maximum of 8 years follow-up. Patients in the sulfonylureas only cohort had increased risks of mortality and cardiovascular mortality, with unadjusted relative risks of 3.12 (95% CI 2.54-3.84) and 3.71 (95% CI 2.64-5.22), respectively. After adjusting for differences between groups (age, sex, duration of diabetes, blood pressure, cholesterol, HbA(1c), smoking, previous hospital admission, treatment with cardiovascular medication), these relative risks were 1.43 (95% CI 1.15-1.77) and 1.70 (95% CI 1.18-2.45), respectively. Patients in the combination cohorts had significantly increased risks of cardiovascular hospital admission, as well as increased risks of mortality and cardiovascular mortality.Conclusions/interpretation In this cohort study of patients newly treated with oral hypoglycaemic agents, those treated with sulfonylureas only, or combinations of sulfonylureas and metformin, were at higher risk of adverse cardiovascular outcomes than those treated with metformin alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-006-0176-9

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
(1998) · PubMed · Cited by 4,290
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
International statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Deprivation and Health in Scotland
Tunstall-Pedoe, H. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.814.665-a · Cited by 1,171
Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death.
Schneider, B. A. (1953) · The Quarterly Review of Biology · doi:10.1086/399926 · Cited by 1,000
Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register
Morris, A. D., Boyle, D. I., MacAlpine, R., Emslie-Smith, A. M., Jung, R. T., Newton, R. W., & MacDonald, T. M. (1997) · BMJ · doi:10.1136/bmj.315.7107.524 · Cited by 297
Self-citation

Flagged first, then by citations

Show all 19 references

Sorted by citations

Items 101–200 of 293

A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 30
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936
Tayek, J. A. (2006) · Diabetologia · doi:10.1007/s00125-006-0404-3 · Cited by 30
Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review
Patorno, E., Garry, E. M., Patrick, A. R., Schneeweiß, S., Gillet, V. G., Zorina, O., Bartels, D. B., & Seeger, J. D. (2015) · Drug Safety · doi:10.1007/s40264-015-0280-1 · Cited by 29
Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries
Landon, B. E., Zaslavsky, A. M., Souza, J., & Ayanian, J. Z. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4310-4 · Cited by 28
A novel thiophene‐3‐carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I
Akatsuka, A., Kojima, N., Okamura, M., Dan, S., & Yamori, T. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.246 · Cited by 26
Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 26
Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
Lee, K. W., Ku, Y. H., Kim, M., Ahn, B. Y., Chung, S. S., & Park, K. S. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.4.340 · Cited by 26
GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects
Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 25
Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham, R. E., & Hanna, A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00700.x · Cited by 26
The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis
Pantalone, K. M., Kattan, M. W., Cheng, Y., Wells, B. J., Arrigain, S., Nutter, B., Jain, A., Atreja, A., & Zimmerman, R. S. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03577.x · Cited by 25
Hypoglycemia Requiring Ambulance Services in Patients with Type 2 Diabetes is Associated with Increased Long-Term Mortality
Parsaik, A. K., Carter, R. E., Myers, L. A., Basu, A., & Kudva, Y. C. (2012) · Endocrine Practice · doi:10.4158/ep12197.or · Cited by 24
Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis
Bell, D. S. H., Patil, H., & O’Keefe, J. H. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0671 · Cited by 25
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 25
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 25
Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
Singh, S. B., Bhat, J., & Wang, P. H. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0327-1 · Cited by 23
Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
Giugliano, D., Standl, E., Vilsbøll, T., Betteridge, J. D., Bonadonna, R. C., Campbell, I. W., Schernthaner, G.-H., Staels, B., Trichopoulou, A., & Farinaro, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0134-3 · Cited by 23
Effect of Metformin-Containing Antidiabetic Regimens on All-cause Mortality in Veterans With Type 2 Diabetes Mellitus
Mangold, T. A., Rawls, W. N., Wall, B. M., Gosmanova, E. O., & Canada, R. B. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31816250e6 · Cited by 23
Coronary heart disease in Type 2 diabetes: mechanisms and comprehensive prevention strategies
Wang, Y., Yu, Q., Fan, D., & Cao, F. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.52 · Cited by 24
Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study
Su, Y., Chen, T., Hsu, C., Chiu, W.-T., Lin, Y., & Chi, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02526 · Cited by 23
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23
Impact of acetylation on tumor metabolism
Zhao, D., Li, F.-L., Cheng, Z., & Lei, Q. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963452 · Cited by 24
Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study
Abdelmoneim, A. S., Eurich, D. T., Gamble, J., Johnson, J. A., Seubert, J. M., Qiu, W., & Simpson, S. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12173 · Cited by 22
Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction — A nationwide study
Jørgensen, C. H., Gislason, G., Bretler, D., Sørensen, R., Norgaard, M. L., Hansen, M. L., Schramm, T. K., Abildstrom, S. Z., Torp-Pedersen, C. T., & Hansen, P. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.07.027 · Cited by 22
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 24
Second line therapy: type 2 diabetic subjects failing on metformin GLP‐1/DPP‐IV inhibitors versus sulphonylurea/insulin: For GLP‐1/DPP‐IV inhibitors
Kumar, A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2350 · Cited by 21
Mortality risk with sulphonylureas compared to metformin
Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12280 · Cited by 22
Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus
Menon, V., & Lincoff, A. M. (2014) · Circulation · doi:10.1161/circulationaha.113.008221 · Cited by 21
The metabolic switch and its regulation in cancer cells
Zhou, S., Huang, C., & Wei, Y. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4041-1 · Cited by 21
Treatment of Hyperglycaemia in Type 2 Diabetic Patients in a Primary Care Population Database in a Mediterranean Area (Catalonia, Spain)
Mata‐Cases, M. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000338 · Cited by 20
Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes
Heaton, P. C., Desai, V. C. A., Kelton, C. M. L., & Rajpathak, S. N. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0084-z · Cited by 20
Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
Santamarina, M. L., & Carlson, C. J. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1036-0 · Cited by 20
National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015
Kitten, A., Kamath, M., Ryan, L., & Reveles, K. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221174 · Cited by 21
Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone
Ye, Y., Lin, Y., Perez-Polo, J. R., & Birnbaum, Y. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6138-3 · Cited by 20
Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus
Guthrie, R. M. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2654 · Cited by 19
Molecular action and pharmacogenetics of metformin: current understanding of an old drug
Rena, G., Pearson, E. R., & Sakamoto, K. (2012) · Diabetes Management · doi:10.2217/dmt.12.42 · Cited by 19
No differences in mortality between users of pancreatic‐specific and non‐pancreatic‐specific sulphonylureas: a cohort analysis
Evans, J. M. M., Ogston, S. A., Reimann, F. M., Gribble, F. M., Morris, A. D., & Pearson, E. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00833.x · Cited by 19
Self-citation
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 18
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1cvalue
Krobot, K. J., Ferrante, S. A., Davies, M. J., Seck, T. L., Meininger, G. E., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.703134 · Cited by 18
Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia–reperfusion injury in rats with diabetes mellitus type 2
Bradić, J., Milosavljevic, I. M., Bolevich, S. S., Litvitskiy, P. F., Jeremic, N. S., Bolevich, S., Zivkovic, V. I., Srejovic, I. M., Jeremic, J. N., Jovicic, N. U., et al. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13450 · Cited by 18
AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents
Anselmino, M. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.07.003 · Cited by 17
Management of diabetes mellitus type-2 in the geriatric population: Current perspectives
Bajwa, S. S., Sehgal, V., Kalra, S., & Baruah, M. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.130956 · Cited by 17
Comparative risk of major cardiovascular events associated with second‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
Zghebi, S. S., Steinke, D. T., Rutter, M. K., Emsley, R., & Ashcroft, D. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12692 · Cited by 17
Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer
Lawrence, W. R., Hosler, A. S., Gates, M. A., Leinung, M. C., Zhang, X., Schymura, M. J., & Boscoe, F. P. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101710 · Cited by 19
Individualized homeopathic treatment in addition to conventional treatment in type II diabetic patients in Hong Kong – a retrospective cohort study
To, K. L. A., Fok, Y., Chong, K. C., Lee, Y. C. J., & Yiu, L. S. S. (2017) · Homeopathy · doi:10.1016/j.homp.2017.02.002 · Cited by 21
Emerging molecular technologies for light-mediated modulation of pancreatic beta-cell function
Chen, Z., Truskinovsky, L. F., & Tzanakakis, E. S. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101552 · Cited by 15
Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013
Pantalone, K. M., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Chagin, K. M., Yu, C., Sakurada, B., Milinovich, A., et al. (2016) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s39761 · Cited by 16
Is metformin a geroprotector? A peek into the current clinical and experimental data
Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16
What is the phenotype of patients with gastrointestinal intolerance to metformin?
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.05.005 · Cited by 18
Occult Cardiotoxicity—Toxic Effects on Cardiac Ischemic Tolerance
Golomb, E., Nyska, A., & Schwalb, H. (2009) · Toxicologic Pathology · doi:10.1177/0192623309339503 · Cited by 16
Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
Davidson, J. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0040-0 · Cited by 15
Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox
Green, J. B. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2767 · Cited by 14
Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus
Azim, S., Baker, W. L., & White, W. B. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0541-0 · Cited by 14
Management of patients with type 2 diabetes
Nelson, S. E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.611797 · Cited by 14
Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs
Jacob, L., Waehlert, L., & Kostev, K. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815607860 · Cited by 14
Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies
Xu, Z., Zhang, H., Wu, C., Zheng, Y., & Jiang, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.944902 · Cited by 14
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
Kim, S. W. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.6.331 · Cited by 14
Acidosis in the hospital setting: is metformin a common precipitant?
Scott, K. A., Martin, J. H., & Inder, W. J. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.01959.x · Cited by 14
Photo-Switchable Sulfonylureas Binding to ATP-Sensitive Potassium Channel Reveal the Mechanism of Light-Controlled Insulin Release
Walczewska-Szewc, K., & Nowak, W. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c07292 · Cited by 13
More Reasons to Say Goodbye to Glyburide
Riddle, M. C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1972 · Cited by 14
Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
Chi, C., SNAITH, J. R., & Gunton, J. E. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.02.030 · Cited by 13
Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease
Monami, M., Marchionni, N., Masotti, G., & Mannucci, E. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.03.135 · Cited by 13
Insulin Tactics in Type 2 Diabetes
Meah, F. A., & Juneja, R. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.021 · Cited by 13
Sulfonilureas en el tratamiento del paciente con diabetes mellitus tipo 2
Sánchez, L. F. P. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76259-4 · Cited by 14
Review of approved pioglitazone combinations for type 2 diabetes
Forst, T. M., Hanefeld, M., & Pfützner, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.567266 · Cited by 12
Pulse pressure and diabetes treatments
Alemi, H., Khaloo, P., Mansournia, M. A., Rabizadeh, S., Salehi‍, S. S., Mirmiranpour, H., Meftah, N., Esteghamati, A., & Nakhjavani, M. (2018) · Medicine · doi:10.1097/md.0000000000009791 · Cited by 12
Association of metformin treatment with enhanced effect of anti-VEGF agents in diabetic macular edema patients
Shao, Y. X., Wang, M., Zhu, Y., Li, X., & Liu, J. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01833-4 · Cited by 12
Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin
Moses, R. G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.17 · Cited by 12
Relation of Severe Coronary Artery Narrowing to Insulin or Thiazolidinedione Use in Patients With Type 2 Diabetes Mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)
Pop‐Busui, R., Lombardero, M., Lavis, V. R., Forker, A. D., Green, J., Korytkowski, M. T., Sobel, B. E., & Jones, T. L. Z. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.046 · Cited by 12
What to add in with metformin in type 2 diabetes?
Petrie, J. R., Adler, A., & Vella, S. (2010) · QJM · doi:10.1093/qjmed/hcq237 · Cited by 11
Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand
Satirapoj, B., Pratipanawatr, T., Ongphiphadhanakul, B., Suwanwalaikorn, S., Benjasuratwong, Y., & Nitiyanant, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-031612 · Cited by 11
Assessing the Impact of Propensity Score Estimation and Implementation on Covariate Balance and Confounding Control Within and Across Important Subgroups in Comparative Effectiveness Research
Girman, C. J., Gokhale, M., Kou, T. D., Brodovicz, K. G., Wyss, R., & Stürmer‎, T. (2013) · Medical Care · doi:10.1097/mlr.0000000000000064 · Cited by 11
Association between intensive glycemic control and mortality in elderly diabetic patients in the primary care: A retrospective cohort study
Ying, D. G., Ko, S. ‐., Li, Y., & Chen, C. X. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.02.012 · Cited by 11
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus
Forst, T. M., Weber, M. M., Löbig, M., Lehmann, U., Müller, J., Hohberg, C., Friedrich, C., Fuchs, W. A., & Pfützner, A. (2010) · Clinical Science · doi:10.1042/cs20100161 · Cited by 11
Cardiovascular disease and type 2 diabetes mellitus: A multifaceted symbiosis
Johansen, O. E. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510701408558 · Cited by 11
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Boyle, L. D., & Wilding, J. P. H. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.831405 · Cited by 10
Type 2 diabetes, metformin and lactic acidosis—defining the risk and promoting safe practice
Senior, P. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03469.x · Cited by 10
Amino acid homeostasis is a target of metformin therapy
Forteath, C., Mordi, I. R., Nisr, R. B., Gutierrez-Lara, E. J., Alqurashi, N., Phair, I. R., Cameron, A., Beall, C., Bahr, I., Mohan, M., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101750 · Cited by 11
Gender Risk of Nonfatal Stroke in Type 2 Diabetic Patients Differs Depending on the Type of Treatment
Khalangot, M. D., Hu, G., Tronko, M. D., Kravchenko, V. I., & Gurianov, V. G. (2008) · Journal of Women s Health · doi:10.1089/jwh.2008.0854 · Cited by 10
The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data
Anagnostis, P. G., Siolos, P., Christou, K., Gkekas, N. K., Kosmidou, N., Athyros, V. G., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0017-5 · Cited by 10
Positioning Metabolism as a Central Player in the Diabetic Heart
Mereweather, L. J., Aparicio, C. N. M., & Heather, L. C. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.92 · Cited by 11
The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes
Khalangot, M. D., Tronko, M. D., Kravchenko, V. I., Kulchinska, J., & Hu, G. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.07.002 · Cited by 10
Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
Rankovic, M. R., Jeremic, N. S., Srejovic, I. M., Radonjić, K., Stojanović, A., Glišić, M., Bolevich, S. S., Bolevich, S., & Jakovljevic, V. L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10005-5 · Cited by 10
Optimizing Antidiabetic Treatment Options for Patients with Type 2 Diabetes Mellitus and Cardiovascular Comorbidities
Malesker, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.193 · Cited by 10
Control de factores de riesgo cardiovascular en pacientes diabéticos revascularizados: un subanálisis del estudio ICP-Bypass
Mazón‐Ramos, P., Cordero, A., González‐Juanatey, J. R., Martínez, V. B., Delgado, E., Vitale, G. C., & Fernández-Anaya, S. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.03.021 · Cited by 9
The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a
Cameron, A., Wallace, K. S., Logie, L., Prescott, A. R., Unterman, T. G., Harthill, J. E., & Rena, G. (2012) · Biochemical Journal · doi:10.1042/bj20112124 · Cited by 9
Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort
Wancewicz, B., Zhu, Y., Fenske, R. J., Weeks, A. M., Wenger, K., Pabich, S., Daniels, M., Punt, M., Nall, R., Peter, D. C., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001493 · Cited by 9
Current and emerging antiglycaemic pharmacological therapies: The renal perspective
Sharif, A. (2011) · Nephrology · doi:10.1111/j.1440-1797.2011.01466.x · Cited by 9
Blood Glucose Control and Coronary Heart Disease
Bianchi, C., Penno, G., Miccoli, R., & Prato, S. D. (2010) · Herz · doi:10.1007/s00059-010-3340-4 · Cited by 9
Metformina: más allá del control glucémico
de Colombia, U. N., Morantes-Caballero, J. A., Londoño-Zapata, G. A., de Colombia, U. N., Rivera, M. R., de Colombia, U. N., Pinilla-Roa, A. E., & de Colombia, U. N. (2017) · Revista Médicas UIS · doi:10.18273/revmed.v30n1-2017005 · Cited by 9
Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936
Johnson, J. A., Simpson, S. H., Eurich, D. T., & Majumdar, S. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0323-3 · Cited by 9
Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications
Paredes, S., Matta-Coelho, C., Monteiro, A. M., Brás, A., Marques, O., Alves, M., & Ribeiro, L. V. P. T. (2016) · HORMONES · doi:10.14310/horm.2002.1671 · Cited by 9
Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin
Li, P., Liu, D., Gao, P., Yuan, M., Zhao, Z., Zhang, Y., Zhou, Z., Zhang, Q., Yuan, M., Liu, X., et al. (2024) · Cancer Innovation · doi:10.1002/cai2.151 · Cited by 10
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
Joshi, P. H., Kalyani, R. R., Blumenthal, R. S., & Donner, T. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.030 · Cited by 8
Insights on the role of anti-inflammatory and immunosuppressive agents in the amelioration of diabetes
Rai, U., Senapati, D., & Arora, M. K. (2022) · Diabetology International · doi:10.1007/s13340-022-00607-9 · Cited by 10
Population-Based Study of Hypoglycemia in Patients with Type 1 Diabetes Mellitus Requiring Emergency Medical Services
Parsaik, A. K., Carter, R. E., Myers, L. A., Geske, J. R., Smith, S. A., Levine, J. A., Basu, A., & Kudva, Y. C. (2012) · Endocrine Practice · doi:10.4158/ep12094.or · Cited by 8
Investigar en diabetes desde una base de datos de atención primaria: la experiencia del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP)
Mata‐Cases, M., Franch‐Nadal, J., Mauricio, D., & Bolíbar, B. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.09.002 · Cited by 8
Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm
Hussain, A. K. B., Abdelgadir, E., Rashid, F., Alhaj, A., Thadani, P., & Bashier, A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.028 · Cited by 9

Authors: Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D.
Affiliations: University of Dundee (GB)
The Mill (GB)
Corresponding author: Evans, J. M. M.
ORCID: Evans, J. M. M.
Morris, A. D.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2006-03-09
Volume: 49
Issue: 5
Pages: 930-936
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-006-0176-9
OpenAlex: W2114349038
Cited by: 293
References: 19
Citations by year: 2026: 2 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 13 · 2018: 15 · 2017: 11 · 2016: 21 · 2015: 13 · 2014: 23 · 2013: 28 · 2012: 24
FWCI: 14.19
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (submittedVersion)
Stirling Online Research Repository (University of Stirling) (submittedVersion, public-domain)
Funders: Diabetes UK
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: type 2 diabetes, sulfonylureas, metformin, oral antidiabetic drugs, cardiovascular mortality, all-cause mortality, cardiovascular hospital admissions, cardiovascular adverse events, combination therapy, newly treated patients
MeSH terms: Adult, Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Female, Hospitalization, Humans, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, Scotland, Sulfonylurea Compounds, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks